Gnubiotics Sciences develops glycopeptide therapeutics that target the Tumor Glycocode to enhance T-cell activity against immuno-oncology resistant cancers, such as colorectal and triple-negative breast cancer. Their lead candidate, GNU101, aims to activate the adaptive immune system, addressing the significant challenge of tumor evasion of immune responses.
Funding
$54M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Immuno-oncology (I/O) resistant cancers, such as colorectal and triple-negative breast cancer, evade the body’s immune response, limiting the effectiveness of existing immunotherapies. Current treatment options often fail to activate a sufficient T-cell response within the tumor microenvironment to overcome this resistance. This results in a significant unmet need for novel therapeutics that can effectively target and eliminate these resistant cancers.
Solution
Gnubiotics Sciences is developing glycopeptide therapeutics designed to break through I/O resistance by targeting the Tumor Glycocode. Their lead candidate, GNU101, is a glycopeptide formulation that promotes cytotoxic T-cell activity within the tumor microenvironment, overcoming tumor resistance. Gnubiotics' glycopeptides activate antigen-presenting cells, instructing cytotoxic T-cells to mount a stronger response against I/O-resistant cancers. The GENESIS platform allows for the design of glycopeptide formulations that match the glycocode of target cancer types, offering a personalized approach to cancer immunotherapy.
Target Audience
The primary target audience includes patients with I/O-resistant cancers, such as colorectal and triple-negative breast cancer, as well as medical centers and researchers focused on developing novel cancer immunotherapies.
Features
- Glycopeptide therapeutics that target the Tumor Glycocode to enhance T-cell activity.
- GNU101 formulation specifically promotes cytotoxic T-cell activity in the tumor microenvironment.
- Activates antigen-presenting cells to instruct cytotoxic T-cells for a stronger anti-tumor response.
- GENESIS platform enables the rational design and manufacturing of precise complex glycopeptide biologics.
- Glycopeptides exhibit dual effects by reinforcing gut epithelial barriers and modulating the local immune response in inflammatory bowel disease.
- Glycopeptides promote microbiome balance by specifically promoting the growth of beneficial bacteria.